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ABSTRACT
Human breast tumors harbor supernumerary centrosomes in almost 80% of 
tumor cells. Although amplified centrosomes compromise cell viability via multipolar 
spindles resulting in death-inducing aneuploidy, cancer cells tend to cluster extra 
centrosomes during mitosis. As a result cancer cells display bipolar spindle phenotypes 
to maintain a tolerable level of aneuploidy, an edge to their survival. HSET/KifC1, 
a kinesin-like minus-end directed microtubule motor has recently found fame as a 
crucial centrosome clustering molecule. Here we show that HSET promotes tumor 
progression via mechanisms independent of centrosome clustering. We found that 
HSET is overexpressed in breast carcinomas wherein nuclear HSET accumulation 
correlated with histological grade and predicted poor progression-free and overall 
survival. In addition, deregulated HSET protein expression was associated with gene 
amplification and/or translocation. Our data provide compelling evidence that HSET 
overexpression is pro-proliferative, promotes clonogenic-survival and enhances cell-
cycle kinetics through G2 and M-phases. Importantly, HSET co-immunoprecipitates 
with survivin, and its overexpression protects survivin from proteasome-mediated 
degradation, resulting in its increased steady-state levels. We provide the first 
evidence of centrosome clustering-independent activities of HSET that fuel tumor 
progression and firmly establish that HSET can serve both as a potential prognostic 
biomarker and as a valuable cancer-selective therapeutic target. 
INTRODUCTION
About 80% of invasive breast cancers exhibit 
supernumerary centrosomes, a feature commonly referred 
to as centrosome amplification [1]. Most breast cancers 
harbor abnormalities in centrosome structure, function, 
or localization within the cell. These abnormalities can 
potentially cause cytoarchitectural distortion in cancer 
tissues with loss of cellular differentiation (anaplasia) via 
altered centrosome function in microtubule nucleation and 
organization [2]. Centrosome amplification can initiate 
tumorigenesis in Drosophila neuroblasts [3]; thus, it is 
becoming recognized that centrosome amplification is 
one of the primary causes of breast cancer and is not just a 
consequence of malignant transformation. 
The presence of more than two centrosomes 
within a cell can pose a grave conundrum as it may lead 
to the assembly of a multipolar mitotic spindle, and the 
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production of nonviable progeny cells due to lethal levels 
of chromosomal loss or gain (i.e., death-inducing, high-
grade aneuploidy) [4]. However, cancer cells harboring 
extra centrosomes circumvent these catastrophic 
consequences and survive. The secret to their survival and 
success, as it turns out, lies in a clever tactic that cancer 
cells use to sidestep spindle multipolarity, viz., centrosome 
clustering, whereby the excess centrosomes are artfully 
corralled into two polar foci to enable formation of a 
pseudo-bipolar mitotic spindle [5, 6]. During a preceding, 
transient, multipolar state, merotelic kinetochore-
microtubule attachments occur, thus engendering low-
grade whole chromosome missegregation that could be 
‘tumor-promoting’ [7]. 
HSET/KifC1, a minus end-directed motor protein 
that promotes microtubule cross-linking, sliding, 
bundling and spindle pole focusing, has been recently 
identified as an essential mediator of supernumerary 
centrosome clustering in cancer cells [8]. HSET has also 
been shown to be indispensable for the clustering of 
acentrosomal microtubule organizing centers (MTOCs) 
whose production tends to be hyperactivated in cancer 
cells. HSET knockdown in cells with supernumerary 
centrosomes causes excess centrosomes to be scattered 
by pole-separating forces, leading to rampant spindle 
multipolarity and cell death [9]. By contrast, HSET 
function appears to be non-essential in healthy somatic 
cells due to the presence of two centrosomes that shoulder 
the responsibility of bipolar spindle assembly. In cells 
devoid of centrosomes, such as oocytes, HSET function 
is indispensable for the assembly of a fusiform bipolar 
spindle [10].  
Recently, attention has converged on HSET as a 
potential chemotherapeutic target due to its intriguing 
association with malignancy. RT-PCR studies have shown 
that HSET’s expression level in lung cancer is associated 
with increased risk of metastatic dissemination to the 
brain [11]. Docetaxel resistance in breast cancer is also 
suggested to be partly mediated by HSET [12]. In silico 
studies reveal that HSET expression is also higher in triple 
negative breast cancers compared to non-triple negative 
ones [13]. The differential dependence of cancer cells on 
HSET for viability and association of HSET expression 
with metastases-raise the tantalizing possibility that HSET 
may play a more important role in tumor progression than 
previously appreciated. However, more direct evidence 
of HSET’s role in clinical progression of breast cancer 
and mechanistic studies revealing the molecular circuitry 
involved therein are lacking. 
In this study, we evaluated HSET expression in 
breast carcinomas and examined its association with 
clinical tumor progression. Intriguingly, we found that 
HSET overexpression at the time of diagnosis was 
significantly associated with worse prognosis and overall 
survival. Exploration of its mechanistic role in tumor 
progression unmasked plausible centrosome clustering-
-independent roles of HSET underlying enhanced tumor 
cell proliferation and survival, and disease progression. 
Our results substantiate the idea that HSET could be an 
invaluable, cancer-cell selective therapeutic target and 
may serve as a prognostic biomarker for breast cancer.
RESULTS
HSET is overexpressed in variety of human 
cancers
Given the crucial requirement of centrosome 
clustering mechanisms for the viability of cancer cells 
with extra centrosomes, we first wanted to examine the 
abundance of the clustering protein HSET in various 
cancers that harbor extra centrosomes. We performed 
an in silico gene expression analysis using publically-
available microarray data to determine the expression 
level of HSET in various cancer tissue types. One-channel 
microarray data for glioblastoma, leukemia, lung and 
breast cancer patients with their normal sample pairs 
were collected from Gene Expression Omnibus (GEO) 
database [14]. Each of these samples were then Robust 
Multiarray (RMA) normalized [15], and their logarithm 
to base 2-transformed HSET gene expression values 
were plotted to determine the difference as shown in 
Fig. 1Ai-vi. Next, we determined differences in HSET 
gene expression for cancer and normal sample groups 
using two-tailed test of hypothesis. Our statistical results 
indicated higher HSET gene expression in glioblastoma, 
lung, breast, colon and cervical tumor samples as 
compared to their corresponding normal tissues. All these 
tumor types have been shown in various studies with 
exhibit significant degrees of centrosome amplification 
[16-25]. The average HSET expression for glioblastoma 
(N=20) and colon cancer (N=53) patients was found 
to be ~3-fold higher than normal samples (N=3 and 
10, respectively) (p<0.005), followed by breast cancer 
patients (N=179) with more than 5-fold higher expression 
in tumors than in normal samples (N=16) (p<0.001). Our 
in silico results were consistent with observations from 
a previous study wherein HSET mRNA expression was 
significantly elevated in a broad panel of primary tumor 
tissue compared to corresponding normal tissue [9]. Our 
in silico data corroborate immunohistochemical analysis 
suggesting a significantly higher HSET expression in 
glioblastoma, colon and cervical tumors (Fig. 1Bii, Cii, 
Dii) as compared with their respective adjacent normal 
tissue samples (Fig. 1Bi, Ci, Di). These data suggest HSET 
overexpression as a general feature of cancers exhibiting 
significant centrosome amplification.
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HSET is overexpressed in human breast cancers
Our in silico analyses of microarray data showed 
that breast cancers display significantly higher HSET 
expression (~5-fold) than corresponding normal tissue. In 
addition, given the pronounced occurrence of amplified 
centrosomes and centrosome clustering in aggressive 
breast cancer, we decided to focus our study on breast 
cancers. To explore the role of HSET in tumor progression, 
we examined whether HSET was overexpressed in human 
breast tumors. We immunoblotted 16 fresh-frozen human 
tumor samples and their paired adjacent normal tissues for 
HSET. An enhanced expression of HSET was observed 
in 10 tumor samples compared to their normal adjacent 
tissues and 7 representative normal/tumor sample pairs are 
shown in Fig. 2A. The remaining 6 normal/tumor pairs 
showed negligible overexpression of HSET (data not 
shown). Additionally, HSET expression in most human 
breast cancer cell lines was much higher than in non-
cancerous or pre-malignant cell lines such as NIH3T3 and 
MCF10 series (MCF10A, MCF10AT1, MCF10DCIS) 
(Fig. 2B), indicating that HSET overexpression typifies 
breast cancer cells. 
Figure 1: HSET overexpression in human carcinomas.  (A) Scatter plots depicting HSET gene expression in normal (green dots) 
versus tumor (red dots) tissues in (i) Glioblastoma, (ii) Lung carcinoma, (iii) Leukemia, (iv) breast carcinoma, (v) colon carcinoma and 
(vi) cervical carcinoma. Data was obtained from one channel microarray available at GEO database. Robust multiarray normalization was 
performed to obtain the differences depicted in the plots. (B, C and D) Immunohistographs showing HSET expression in glioblastoma 
tissue where a representative normal tissue (N) (Bi) is compared to tumor tissue (T) (Bii), in colon tumor (Cii) versus adjacent normal (Ci) 
tissue, and in cervical tumor (Dii) versus adjacent normal (Di) tissue. 
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Since higher HSET protein levels could arise either 
from an upregulation of transcription from the endogenous 
locus and/or an amplification of the locus encoding HSET, 
we decided to examine the copy numbers of the locus 
encoding the HSET gene in normal and breast tumor 
tissues. We performed fluorescence in situ hybridization 
(FISH) to directly evaluate HSET copy number per cell 
in paraffin-embedded breast tumor tissues. We hybridized 
two bacterial artificial chromosome (BAC) probes to 
primary breast tumor tissues, one from the HSET locus 
on chromosome 6 (RPCI-11 602P21, green) and one 
from the chromosome 6 centromere (CH514-7B4, red). 
Amplification of HSET was visualized as an increase in 
the number of HSET signals relative to the number of 
control centromere signals. We scored HSET amplification 
by FISH in four breast tumor tissues and found that, 
among them, three tumors exhibited HSET amplifications. 
No amplification of the HSET locus was observed in the 
normal adjacent tissues in these samples. We observed 
various types of copy number changes associated with 
HSET as shown in Fig. 2C, D. FISH with the centromere 
probe indicated that most increases in HSET loci were not 
due to polyploidy of chromosome 6; rather, only 5% of 
cells were aneuploid. 38% of cells (500 cells each were 
counted from 2 tissue samples) showed 3 or more copies 
of HSET paired with only 1 or 2 copies of the centromere 
(Fig. 2D). More so, cancer cells isolated from fresh human 
breast tumor also showed HSET amplification (Suppl. Fig. 
1). These findings indicate alterations in the HSET gene 
copy number during tumorigenesis. It is worth mentioning 
that HSET gene amplifications in specific breast tumor 
samples were correlated with increased expression of 
HSET protein in all those samples using immunoblotting 
methods (data not shown).
HSET overexpression correlates with breast 
cancer progression and aggressiveness
Next we asked how HSET overexpression correlates 
with breast cancer progression and aggressiveness. 
Using an immunohistochemical approach, we stained 
a total of 60 clinical specimens with 10 cases each of 
normal breast, ductal hyperplasia (DH), atypical ductal 
hyperplasia (ADH), ductal carcinoma in situ (DCIS), 
invasive breast carcinoma (low-grade) and invasive 
breast carcinoma (high-grade). In consonance with our 
immunoblotting data, our immunohistochemical analysis 
showed that HSET is selectively overexpressed in human 
breast cancers with negligible or absence of expression 
in normal breast epithelia (Fig. 3A). Intriguingly, we 
observed a selective increase in nuclear staining of HSET 
Figure 2: The HSET gene is overexpressed in breast cancers. (A) Cell lysates from 16 paired clinical breast tumor tissues (T) and 
normal adjacent tissues (N) were analyzed for HSET protein expression by western blotting. Representative results of 7 paired samples are 
shown. (B) Immunoblot showing HSET expression in a) MCF10A series of cell lines representing a continuum from near-normal breast 
(MCF-10A) to pre-malignant (MCF10-AT1) to comedo ductal carcinoma in situ (MCF10-DCIS), aggressive breast cancer cell lines such 
as MDA-MD-231 and T47D and normal mouse fibroblast cell line, 3T3. (C) Representative confocal micrographs showing fluorescence 
in situ hybridization of two bacterial artificial chromosome (BAC) probes, one from the HSET locus on chromosome 6 (RPCI-11 602P21, 
green) and one from the chromosome 6 centromere (CH514-7B4, red), to paraffin-embedded primary breast tumor tissues. Amplifications 
of HSET were visualized as an increase in the number of green signals (denoted as G) relative to the number of red control centromere 
signals (denoted as R), where 1R1G and 2R2G represent normal HSET gene copy numbers and 1R4G, 2R4G, 2R5G, 1R5G,etc. represent 
instances wherein HSET gene locus is amplified. (D) Bar graph representation of various combinations of red and green copy numbers 
observed for HSET locus and chromosome 6 centromere as determined by visual quantitation from confocal images (p<0.05). 1R1G and 
2R2G are considered normal copy numbers; elevated copy numbers but same ratio of R and G signals are considered as aneuploid (3R3G, 
4R4G) and all other combinations with higher G-to-R ratios are considered to represent instances where the HSET gene is amplified.
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in tumor samples. Among subtypes based on varying 
types and extent of intraductal proliferation, we found a 
progressive increase in HSET nuclear staining intensity 
and frequency from ductal hyperplasia (DH) (Fig. 3Aii) 
to atypical ductal hyperplasia (ADH) (Fig. 3Aiii) to 
ductal carcinoma in situ (DCIS) (Fig. 3Aiv). In invasive 
breast cancers (both low- and high- grade), HSET nuclear 
staining was remarkably intense, with a significant 
increase in the number of positively stained nuclei per 
field in high-grade cancers (Fig. 3Av,vi) compared to low-
grade ones (Fig. 3Aii,iii,iv). A majority of normal breast 
tissue samples (85%) showed no staining for HSET, while 
the remainder showed very weak staining (Fig. 3Ai, data 
not shown). We then calculated a weighted index score 
(WI) for HSET expression as a product of the staining 
intensity score (+1, +2, +3) and percentage positive nuclei 
for each sample. HSET WI serves as an independent 
measure of the strength of HSET protein expression across 
all breast tumor specimens. Nuclear HSET WI values were 
then correlated with normal and tumor samples and also 
with the grade of tumor samples. Interestingly, nuclear 
HSET WI showed a strong correlation with increasing 
tumor grade in breast cancer (Fig. 3Bi,ii). Collectively, 
these observations indicate robust HSET overexpression 
Figure 3: HSET overexpression correlates to increased aggressiveness and poorer clinical outcomes. Immunohistographs 
showing HSET expression in (Ai) normal breast, (Aii) ductal hyperplasia, (Aiii) atypical ductal hyperplasia, (Aiv) ductal carcinoma in-
situ, (Av) invasive ductal carcinoma, low-grade, (Avi) invasive ductal carcinoma, high-grade. Brown (DAB) color shows HSET staining. 
Intensities of nuclear HSET staining were quantified using image analysis Aperio Image Scope v.6.25 software. A weighted index score 
(WI) for HSET expression was calculated and was assessed in 339 breast cancer and 19 normal samples. Box-whisker plots showing (Bi) 
HSET WI score in normal breast and tumor samples, (Bii) HSET WI score across Grade I (n=40), Grade II (n=237) and Grade III (n=62) 
breast cancer samples. (Ci) Probability of progression free survival of 163 breast cancer patients with HSET nuclear expression above 
or below the median HSET weighted index (WI) value referred to as positive and negative, respectively (p=0.0034). (Cii) Probability of 
overall survival of 163 patients with positive and negative HSET weighted index (p=0.0412). Statistical analysis was conducted using SAS 
Version 9.3. Scale bar=10 µm. 
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in human breast tumors suggesting that abnormal HSET 
levels correlate with breast cancer development and 
HSET might play a role in progression of tumors into 
more malignant and aggressive forms. Having established 
a significant correlation between HSET expression and 
tumor differentiation, we next asked if there was an 
association of nuclear HSET WI with progression-free 
survival (PFS) and overall survival (OS) in breast cancer 
patients, using the biospecimens obtained from Emory 
Hospital with retrospective clinical information (n=163). 
While PFS was calculated as the number of days from 
diagnosis to the first local recurrence or metastasis if 
one occurred, or the last follow-up if the patient did not 
progress, OS was based on the number of days from 
diagnosis to death or last follow-up if death was not 
recorded. Nuclear HSET WI was also categorized into 
high and low groups based on the median. Irrespective 
of the receptor status (n=163), those with higher nuclear 
HSET WI (shown as HSET WI positive in Fig. 3Ci,ii) had 
significantly shorter PFS (p= 0.0034) and OS (p=0.0412) 
than patients with lower nuclear HSET WI (shown as 
HSET WI negative in Fig. 3Ci,ii), clearly demonstrating 
that higher nuclear HSET expression levels significantly 
correlate with poorer clinical outcomes. Multivariate 
analysis accounting for HSET nuclear expression, age, 
grade and receptor status (ER, PR, HER2) revealed that 
HSET nuclear expression and receptor status (negative) 
significantly correlated with both OS (p=0.030 for nuclear 
HSET WI, p=0.036 for PR negativity) and PFS (p=0.044 
for nuclear HSET WI, p=0.003 for HER2 negativity). 
Mean HSET was significantly higher (7.82 vs 5.50, p 
<.0001) for triple-negative patients as opposed to non-
triple-negative patients. In a wound-healing assay, we 
show that HeLa cells transiently overexpressing HSET 
show enhanced migration as compared to wild-type HeLa 
cells (Suppl. Fig. 2). These observations strongly suggest 
correlation of HSET nuclear expression with breast tumor 
aggressiveness.
Figure 4: Cell proliferation is enhanced in HeLa cells that stably overexpress HSET. (A) Immunoblots showing higher 
Ki67 and p-histone H3 in HeLa-HSET-GFP (denoted as HeLa HSET) cells as compared with HeLa cells. Kinase activity assay showed 
higher cdk1 activity in HeLa-HSET-GFP cells as represented by the immunoblot showing enhanced phosphorylation of Histone H3 by 
cdk1 as compared to HeLa cells. The two bands representing HSET expression correspond to the endogenous HSET levels (lower band) 
and the GFP-HSET levels (upper band). (B) Representative confocal immunomicrographs showing higher Ki67expression (red) in HeLa-
HSET-GFP cells as compared with HeLa cells. (C) Randomly dividing HeLa-HSET-GFP and HeLa cells were incorporated with BrdU 
and immunostained with anti-BrdU antibody (green) to visualize the cells traversing S-phase. Representative immunofluorescence images 
showing higher BrdU incorporation in HeLa-HSET-GFP cells. (D) Bar graphs depicting the percent cells that are Ki67or BrdU positive in 
HeLa and HeLa-HSET cells. (E) Bar graphs representing number of cells in cell proliferation assay counted by trypan blue at Day 0 and 
Day 2 of seeding.
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HSET overexpression is associated with enhanced 
cell proliferation
Since elevated HSET expression exhibits a strong 
correlation with clinical development and progression of 
cancer, we next asked if high HSET levels had any impact 
on the kinetics of cancer cell proliferation in vitro. To this 
end, we used HeLa cells stably transfected with HSET-
GFP to examine and compare the levels of various cell 
proliferation markers in HeLa-HSET-GFP and HeLa cells. 
Using immunoblotting methods, we found that levels of 
Ki67 (found in G1, S, G2 and M-phases of the cell cycle 
but is absent in G0 cells) was substantially elevated in 
HeLa-HSET-GFP cells compared to wild-type HeLa cells 
(Fig. 4A). This finding was consistent with the strikingly 
higher Ki67 labeling index observed in HeLa-HSET-GFP 
cells via immunostaining (Fig. 4B). This observation is 
noteworthy since the Ki67 labeling index often correlates 
with the clinical course of cancer, owing to which the 
proportion of Ki67-positive cells in a cell population has 
strong prognostic value for survival and tumor recurrence 
in cancer patients [26, 27]. Immunofluorescent staining 
for BrdU, a marker for cells undergoing S-phase, also 
showed that a greater proportion of HeLa-HSET-GFP 
cells were BrdU-positive compared to HeLa cells (Fig. 
4C). A visual quantitation of these observations revealed 
significantly elevated levels of Ki67 expression and BrdU 
incorporation in HeLa-HSET-GFP cells as compared 
with HeLa cells (Fig. 4D). We also observed enhanced 
cdk1 activity and higher expression of phosphorylated 
histone-H3 in HeLa-HSET-GFP cells compared to HeLa 
cells, which is indicative of a larger proportion of cells 
in the HeLa-HSET-GFP line undergoing M-phase (Fig. 
4A). All these lines of evidence strongly advocate for 
a pro-proliferative role for HSET overexpression in the 
cellular context of cancer cells. HeLa-HSET-GFP cells 
also displayed significantly enhanced cell proliferation 
capacities when compared to HeLa cells in trypan blue 
assay. Equal numbers of each cell type were seeded on 
day 0 and were allowed to grow for 2 days (48h), and 
the number of cells were counted using trypan blue. 
Based on the data, the doubling time of HeLa-HSET-
GFP cells was found to be ~11h as compared to ~16h 
for HeLa cells (Fig. 4E). We also performed colony 
formation assay with HeLa cells transiently transfected 
with control vector, HSET-GFP plasmid and HSET-GFP 
siRNA. HSET OE cells were able to form significantly 
higher number of colonies as compared to cells transfected 
with control vector. Fewer colonies were observed 
upon HSET knockdown (KD) (Suppl. Fig. 3). Similar 
proliferation effects were confirmed by colony formation 
assay in another breast cancer cell line, MDA-MB-231 
upon transient HSET OE and KD (Suppl. Fig. 3). Taken 
together, these data demonstrate that cells overexpressing 
HSET display enhanced cell proliferation, and suggest that 
HSET overexpression may confer significant proliferative 
advantages to cancer cells.
HSET overexpression leads to accelerated cell 
cycle kinetics
Since HSET OE enhances cellular proliferation 
in HeLa cells, we were curious to examine any changes 
in the cell cycle kinetics of cells that stably overexpress 
HSET (HeLa-HSET-GFP cells) compared to the parental 
ones. To this end, we synchronized HeLa and HeLa-
HSET-GFP cells using a single thymidine block (19h) 
followed by 2-color flow cytometric analysis of cell cycle 
profiles of HeLa-HSET-GFP and HeLa cells upon their 
release from the block at G1/S border. DNA content was 
analyzed with propidium iodide (PI) staining, where G2/M 
population was represented by double the intensity of PI 
(4N) compared to G1 cell population (2N). Anti-MPM-2 
antibody tagged with Alexa488 secondary antibody was 
used to detect a mitosis-specific marker (MPM-2), in 
order to distinguish between 4N DNA-bearing G2 and M 
populations. A close interval cell cycle profiling revealed 
that HeLa-HSET-GFP cells demonstrated faster cell cycle 
progression kinetics; in other words, the duration of one 
complete cell cycle was reduced in HeLa-HSET-GFP cells 
(10.5h) as compared with wild-type cells (13h), with a 
stark shortening of the G2-and M-phases (Fig. 5A, B, C). 
This experiment was performed 3 times and the average 
time was represented as final duration of cell cycle phases 
in Fig. 5A. This trend was reflected when cyclin B1 levels 
(indicating mitotic phase) were followed in synchronized 
HeLa and HeLa-HSET-GFP cells using western blotting. 
While cyclin B1 levels surged at 10h followed by a decline 
in HeLa cells, they peaked at 8h and then declined in 
HeLa-HSET-GFP cells (Fig. 5D). Transient knockdown 
(KD) of HSET in HeLa cells resulted in a marginal 
increase in cell cycle duration (14h as compared to 13h 
in HeLa cells) with a protracted G2/M-phase (Suppl. Fig. 
4A). This observation is in accordance with previously 
observed effects of HSET depletion in human fibroblast 
cells leading to delayed cyclin A degradation [28]. 
Most often, G1-phase contributes significantly to the 
cell cycle duration; thus, we sought to determine the effect 
of HSET OE and KD on G1-phase kinetics. Upon gradual 
decrease of serum concentration from 10% to 0% over 
24h and an additional 12hr serum starvation, transiently 
transfected HeLa control vector (CV), HeLa HSET OE 
and HeLa HSET KD cells were replenished with serum-
containing medium and stained with “Cell-Clock” dye 
(Biocolor; a redox dye that changes color corresponding 
to distinct phases in cell cycle). Yellow cells in the culture 
represent G1 and their color changes to light green in 
S-phase. We followed the proportion of G1 (yellow-
colored) cells from 0h (50-70% G1 enrichment) to 9h after 
serum replenishment in all the three cases (CV, OE and 
KD). We observed negligible differences in the proportion 
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of G1 cells in all three conditions (Suppl. Fig. 4Bi, Bii). 
This suggests that unlike G2-and M-phase kinetics, HSET 
OE does not significantly affect the duration of G1-phase.
Faster kinetic progression of HeLa-HSET-GFP cells 
(through G2- and M) compared to HeLa cells raised the 
possibility that G2/M or spindle assembly checkpoint 
(SAC) functions may be compromised in HeLa-HSET-
GFP cells. Mad1 is a critical component of the SAC 
along with Mad2, and an imbalance in the Mad1-Mad2 
protein ratio results in a damaged SAC causing premature 
anaphase entry and chromosome instability [29, 30]. 
Interestingly, we found that HeLa-HSET-GFP cells 
express markedly higher levels of Mad1 with a distinct 
nuclear envelope localization compared with parental 
HeLa cells (Fig. 6A, B). This observation along with 
the known association of HSET with importins, indicate 
that HSET might be involved in regulating mitotic entry/
exit and nuclear export [31]. By contrast, there was no 
Figure 5: HSET overexpression accelerates cell cycle kinetics. (A) Schematic depicting duration of each cell cycle phas  in 
HeLa and HeLa-HSET-GFP cells assessed by flow cytometry following synchronization at G1/S border by single thymidine block.. (B) 
Cell cycle histograms representing cell cycle profiles of synchronized (i) HeLa and (ii) HeLa-HSET-GFP cells from the point of thymidine 
block release (0h) to the point after mitotic exit (14h and 11h, respectively). (C) Dot plots of PI (DNA) vs FITC (MPM-2) showing cells in 
G2- (lower box) and M-phase (upper box) specifically during the time of mitotic exit in (i) HeLa and (ii) HeLa-HSET-GFP cells. Two-color 
scatter plot (PI vs. GFP) shows two box gates, where the lower box represents G2 population (PI-4N and FITC negative) and upper box 
represents M population (PI-4N and FITC positive). G2/M population was represented by double the intensity of PI (4N) as compared with 
G1 population (2N). Mouse anti-MPM-2 antibody tagged with anti-mouse Alexa-488 secondary antibody was used as a mitosis-specific 
marker, to distinguish G2 and M populations. The time for mitotic exit was determined by assessing the population in the upper gate of 
the 2-color scatter plot. A sudden surge in the proportion of mitotic population followed by a rapid fall indicated the time of mitotic exit. 
13h was observed as the time of mitotic exit for HeLa cells whereas, 10.5h was the time of mitotic exit for HeLa-HSET-GFP cells. (D) 
Immunoblots showing cyclin B1 protein levels in synchronized HeLa and HeLa-HSET-GFP cells following release from thymidine block 
at G1/S boundary. 
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significant difference in the levels of Mad2 between the 
two cell lines (Fig. 6A), showing that the Mad1-Mad2 
balance is highly perturbed in the HeLa-HSET-GFP cells. 
Thus we envision that excess HSET directly or indirectly 
incapacitates the SAC by disrupting the Mad1/Mad2 
balance. The HeLa-HSET-GFP cells thus progress through 
the cell cycle rapidly in the presence of compromised 
checkpoints, which precipitates a greater likelihood of 
generating aneuploidy and, thus, may accelerate the 
process of tumor evolution. 
Our data from the HeLa-HSET-GFP cells 
demonstrate that HSET OE can markedly accelerate the 
kinetics of G2 and M (Fig. 5A, B, C). Intriguingly, our 
immunohistochemical data from clinical tumor samples 
(Fig. 3A) showed strong nuclear localization of HSET. In 
order to obtain a deeper understanding of how elevated 
HSET levels may hasten progression through G2-and 
M-phases of the cell cycle and to exclude the possibility 
that faster kinetic progression through the cell cycle 
may result from artifactual mislocalization of HSET, we 
decided to examine in detail the sub-cellular localization 
of this intriguing protein in HeLa cells at various cell cycle 
stages. We found that HSET is conspicuously confined 
to the nucleus throughout interphase (Suppl. Fig. 5). 
Our observations are consistent with the finding that the 
Xenopus homolog of HSET, XCTK2, is sequestered in 
the nucleus in interphase in a Ran-dependent manner via 
the association of the NLS of XCTK2 with importin α/β 
[32]. In summary, the nuclear localization of the human 
HSET protein in interphase strongly suggests that the 
acceleration of the kinetics of G2 may be ascribed to a 
hitherto unknown activity of HSET within the nucleus.
HSET overexpression upregulates survival 
signaling in cancer cells
Tumor cell numbers and tumor growth are not only 
a function of rate of cell proliferation but are also crucially 
influenced by cell survival and/or apoptosis. Having 
ascertained that HSET OE can enhance the kinetics of cell 
proliferation in tumors, we wanted to investigate whether 
elevated levels of HSET have any impact on the status of 
pro-survival signaling in HeLa cells. Immunoblots showed 
enhanced survival signaling as evidenced by notably high 
survivin and p-Bcl2 levels in HeLa-HSET-GFP cells (Fig. 
6C) compared with levels seen in parental HeLa cells. To 
investigate if HSET OE affects signaling pathways that 
impinge on cell proliferation, or cell survival in breast 
cancer cells, we compared levels of some key proliferation, 
hypoxia and cell survival markers in parental MDA-
MB-231 cells with MDA-MB-231-HSET overexpressing 
cells and MDA-MB-231-HSET knockdown cells. We 
observed enhanced levels of survivin and phospho-
survivin, the hypoxia-induced factor HIF1α, the SAC 
protein Mad1 and the mitotic kinase Aurora-B in MDA-
MB-231-HSET overexpressing cells (Fig. 6D). However, 
upon HSET knockdown, marginal or no reduction was 
observed in the expression levels of these proteins as 
compared with their respective levels in control cells (Fig. 
6D). We also observed enhanced Aurora-B kinase activity 
as well as elevated expression of cyclin B1, D and A upon 
HSET overexpression in MDA-MB-231 cells (Suppl. Fig. 
6A). The differential effects observed upon HSET OE 
and KD indicated that HSET may not normally be a key 
regulator of proliferation and survival pathways. Several 
studies [33] have in fact shown that HSET function 
is dispensable for the viability of most non-cancerous 
cells. However, our OE data strongly suggest that an 
elevated level of HSET expression thrusts proliferation 
and survival signaling in cancer cells into an “overdrive” 
mode. Using immunohistochemical analysis, we also 
confirmed that HSET nuclear WI correlated strongly 
with survivin WI (r=0.68, p=0.05) and Ki67 WI (r=0.32, 
p<0.001) in clinical samples (n=163). In summary, while 
HSET plays a non-essential role in regulating survival 
signaling in cancer cells, HSET overexpression enhances 
both proliferation as well as survival of cancer cells and 
perhaps fuels tumor progression by providing cancer cells 
with a proliferation and survival advantage. Our data thus 
provide evidence that cancer cells may employ auxiliary 
pathways/mechanisms, such as those involving the kinesin 
motor HSET, to their advantage.
To further explore the physiological role of HSET in 
cell survival signaling, we assessed the ability of MDA-
MB-231 cells with HSET OE or KD to resist UV-induced 
apoptosis. To this end, we transiently transfected MDA-
MB-231 cells with control vector, HSET OE construct 
or HSET siRNA (~70% transfection efficiency) 24h 
prior to UV irradiation. Following 10 min exposure to 
UV-C at 25 J/m2, cells were placed in the incubator for 
apoptosis induction for 5h. Lysates were then collected for 
determining HSET and cleaved caspase-3 protein levels 
(an early marker for apoptosis induction) and cell viability 
was determined using trypan blue assay. Western blot 
analysis revealed significantly higher cleaved caspase-3 
induction in cells with HSET knock-down, whereas cells 
with HSET OE showed slightly lower cleaved caspase-3 
levels as compared to cells transfected with control 
vector (Fig. 6E). These data indicate the ability of HSET 
overexpression to promote cell survival in cancer cells. 
HSET overexpression increases steady-
state survivin levels by decreasing its poly-
ubiquitination
Since we observed extensive upregulation of 
survivin protein expression as a result of HSET OE and 
significant reduction upon HSET KD, we wanted to 
determine if HSET occurs in the same protein complex 
as survivin and whether HSET OE has any effect on the 
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APC/C-dependent proteolysis of survivin.
First, we tested if HSET and survivin 
co-immunoprecipitate with each other. We 
immunoprecipitated HSET from whole cell lysates of 
MDA-MB-231 cells that carried (i) a control vector, 
(ii) an HSET OE plasmid, and (iii) an HSET siRNA-
bearing construct. Upon probing the immunoprecipitates 
for survivin, we confirmed that the anti-HSET antibody 
was able to pull down survivin in all the three cases, 
with an increased survivin pull down in the cell lysates 
overexpressing HSET (Fig. 6Fi). We also confirmed this 
association by immunoprecipitating survivin and in turn 
probing with HSET antibody (Suppl. Fig. 6B). These data 
indicate that HEST binds to survivin either directly or 
indirectly. 
Since survivin’s role in prosurvival signaling is 
Figure 6: HSET overexpression upregulates survival proteins and disrupts balance of checkpoint proteins. (A) 
Immunoblots showing HSET, Mad1 and Mad2 protein levels in HeLa and HeLa-HSET-GFP cells. β-actin is used as a loading control for all 
western blots. (B) Immunofluorescence micrographs showing Mad1 (green) levels and localization in HeLa and HeLa-HSET-GFP cells. (C) 
Immunoblots showing the expression levels of survival proteins (survivn, p-Bcl2) in HeLa and HeLa-HSET-GFP cells. (D) Immunoblots 
showing the expression of proteins associated with cell survival, cell cycle regulation, spindle assembly checkpoint and adaptation to 
hypoxia in MDA-MB-231 cells (C) compared to MDA-MB-231 cells transiently transfected with HSET-pEGFP plasmid (OE) or HSET 
siRNA (KD). (E) Immunoblots showing HSET and cleaved caspase-3 protein expression in MDA-MB-231 cells transiently transfected 
with vehicle control, HSET pEGFP plasmid or HSET siRNA, followed by UV-C exposure at 25 J/m2 for 10 min. (Fi) Immunoblots showing 
HSET and survivin protein levels in MDA-MB-231 with control vector (CV), with HSET overexpression and with HSET knockdown 
when HSET was immunoprecipitated (HSET IP) or not immunoprecipitated (beads only) followed by immunoblotting against survivin. 
(Fii) Immunoblots showing survivin immunoprecipitated from MDA-MB-231 cells (CV, OE and KD) and imuunoblotted agaist surviving 
and ubiquitin. (G) Schematic model depicting the involvement of HSET in tumor progression and metastasis via a) previously established 
mitotic pathways (Green boxes) and interphase-specific pathways suggested by our data (blue boxes). Dotted arrow indicates an unknown 
and indirect modulation of various downstream pathways by overexpressed nuclear HSET. C= control GFP vector.
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strongly regulated by its degradation via ubiquitination 
[34], we further set out to test the possibility that 
increased HSET binding to survivin protects survivin 
from ubiquitination and APC/C-dependent degradation. 
In MDA-MB-231 cells transiently transfected with 
control vector, HSET-GFP plasmid and HSET siRNA, 
we immunoprecipitated survivin and immunoblotted 
against survivin and ubiquitin. Intriguingly, we observed 
reduced polyubiquitin signals in HSET overexpressing 
cells, even though survivin protein levels were extensively 
overexpressed in HSET overexpressing cells (Fig. 6Fii) as 
observed earlier (Fig. 6D). We also observed marginally 
higher ubiquitin levels in HSET KD cells as compared 
to control, even though the survivin protein levels 
were comparable in both the cases (Fig. 6Fii). These 
observations, in sum, uncover a previously unrecognized 
role of HSET overexpression in tumor progression via 
supplementing prosurvival pathways (Fig. 6G). 
DISCUSSION
In recent years, the key role played by the 
kinesin-14 protein HSET/KifC1 in centrosome clustering 
in cancer cells with supernumerary centrosomes, has 
been well established. In addition to its mitotic spindle-
specific roles, several other roles of HSET requiring or 
independent of its motor activity have been suggested such 
as a role in processing early endocytic vesicles [35], rat 
spermatogenesis [36] and active transport of bare double-
stranded DNA [37]. Although it is presently unclear 
whether HSET performs all these functions in cancer cells, 
these studies bring to light the possibility that HSET’s 
involvement in tumor biology could be multifaceted.
We (Fig. 1A,B) and others [9] have found that a 
variety of primary tumors overexpress HSET as compared 
to their normal adjacent tissues. Several other threads 
of largely correlative and circumstantial evidence have 
suggested an involvement of HSET in driving tumor 
progression and metastases [9, 11]. However, our study 
is the first to explore and obtain several new mechanistic 
insights into the pathology of excess HSET in breast 
cancer cells. We have firmly cemented the hitherto 
anecdotal evidence with experimental data to show 
that HSET OE in breast cancer (i) correlates strongly 
with aggressiveness of the disease, (ii) is attributable, 
at least in part, to amplification of the genomic locus 
for this gene, and (iii) promotes tumor cell proliferation 
by accelerating cell cycle kinetics. Given the myriad of 
clinical implications of these important findings, our study 
spotlights the tremendous potential that HSET presents 
both as a biomarker of tumor progression and as an 
invaluable cancer cell-specific therapeutic target. 
Four critical observations lead us to believe that 
HSET might have additional roles in driving tumor 
progression, independent of its centrosome clustering/
spindle pole focusing role in mitosis, viz., (i) elevated 
‘nuclear’ expression of HSET predominantly in the 
interphase cells within high grade tumors as revealed 
by immunohistochemical staining suggests that HSET 
may perform critical mitosis-independent functions in 
aggressive tumors or plausibly lead to more aggressive 
phenotypes within tumors; (ii) overexpression of HSET 
results in accelerated G2- and M-phases. Faster mitoses 
can conceivably arise from severely compromised SAC 
function that presumably allows HSET-overexpressing 
cells to rapidly traverse mitosis in the presence of 
aberrations including chromosome attachment errors. 
However, we are aware of the caveat that this mitotic 
role of HSET does not provide an alibi for the observed 
faster progression through the G2-phase upon HSET 
overexpression; (iii) HSET OE in HeLa cells leads 
to faster cell-cycle kinetics and enhanced overall 
proliferation (Fig. 5A, B, C), and (iv) HSET OE leads to 
the upregulation of the expression of phospho-survivin, 
Bcl-2, HIF1α, Aurora-B and Mad1, and presumably 
upregulates the signaling pathways that lie downstream 
of these key regulatory factors. Furthermore, since fewer 
than 3% of HeLa cells possess amplified centrosomes 
(our unpublished observations), we believe that the pro-
proliferative role of HSET that we have demonstrated in 
our study in HeLa cells provides strong evidence for a 
centrosome clustering-independent activity of HSET. 
To further support the centrosome clustering-
independent aspect of HSET’s role in driving tumor 
survival and proliferation, we assessed the effects 
of HSET OE and KD in HeLa cells with or without 
centrosome amplification. We induced extra centrosomes 
in HeLa cells by aphidicolin treatment (20 µM for 48h) 
and then compared the effect of HSET OE on expression 
of proliferation/survival markers in the HeLa cell lines 
bearing normonumerary and supernumerary centrosomes. 
The fact that we were able to show higher expression of 
proliferation and survival proteins upon HSET OE in the 
same cell line regardless of its centrosome status (Suppl. 
Fig. 7), asserts the centrosome clustering-independent 
role of HSET in driving cell proliferation and survival. 
Our data showed that HSET OE leads to an increase in 
Mad1 levels without any significant change in the levels 
of its partner protein, Mad2. Mad1 overexpression in 
HeLa cells has been shown to disrupt the stoichiometric 
balance between Mad1 and Mad2 to severely cripple 
SAC function leading to aneuploidy and chromosomal 
instability [29, 30]. We postulate that this surge in 
Mad1 protein levels (Fig. 6A, B) facilitates premature 
anaphase entry by titrating the soluble pool of Mad2 
and thereby damaging SAC function, and provides a 
possible explanation for the speedier execution of mitosis 
in HeLa-HSET-GFP cells. In addition, our study has 
yielded several novel mechanistic insights regarding the 
signaling pathways governed by HSET. Our data indicate 
that HSET is actually a key member of an oncoprotein 
axis that includes HIF1α and Aurora-B, and controls 
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survival signaling through phospho-survivin and Bcl-2 
(Fig. 6A, C, D). The dysregulation of HIF1α and Aurora-B 
are implicated in many aspects of cancer development 
and advancement [38, 39]. Notably, HIF1α drives the 
expression of survivin, which performs a dual function: 
it is an anti-apoptotic protein that additionally promotes 
cell proliferation [40-42]. Aurora-B is a chromosomal 
passenger protein involved in chromosome segregation, 
the spindle checkpoint and cytokinesis [43]. Aurora-B 
overexpression, observed in several tumor types [44], has 
been linked with aggressive metastasis and poor prognosis 
of cancer patients [45, 46]. Our data thus suggest that 
HSET OE-driven elevation in HIF1α and Aurora-B 
kinase levels incites upregulation of the pro-proliferative 
and pro-survival signaling networks and together with the 
increased aneuploidy triggered by impaired SAC function, 
facilitates tumor evolution into more malignant forms. 
Importantly, our immunoprecipitation experiments 
demonstrate that both HSET and survivin exist within 
the same complex in MDA-MB-231 cells. We further 
investigated the molecular and functional significance 
of HSET’s association with survivin and uncovered 
that HSET binding to survivin protects survivin from 
degradation by interfering with the latter’s ubiquitination. 
It has been shown that survivin ubiquitination and 
degradation occurs in the nucleus. We propose that 
high levels of nuclear HSET inhibit the ubiquitination-
dependent proteolysis of survivin in the interphase 
nucleus of cancer cells. Survivin accumulation is known to 
increases Aurora-B kinase activity, which in turn,vincrease 
the endogenous levels of phosphorylated histone H3; 
clearly, we observe all these effects following HSET OE 
(Fig. 6). Thus, we have provided mechanistic evidence 
that HSET OE, by stabilizing survivin, leads concurrently 
to both increased cell proliferation and survival signaling.
A recent study revealed HSET (along with other 
cell cycle regulated genes) as a transcriptional target of 
p110CUX1 [47]. Constitutive activation of p110CUX1 
is known to drive cell proliferation by expediting entry 
into S-phase [48]. Interestingly, Mad1 is also shown to be 
transcriptionally regulated by p110CUX1 [49]. In light of 
these insights, we are unable to rule out the possibility that 
HSET nuclear overexpression and upregulation of Mad1 
levels are a mere consequence of an upstream regulation 
by classical tumor promoting genes. The Cux1-E2F-HSET 
cell proliferation axis thus demands further exploration in 
order to substantiate the validity of this prospect. Besides, 
we cannot discount the significance of substantial cell 
cycle effects observed upon HSET overexpression and the 
unyielding relationship between HSET nuclear expression 
and patient survival. 
Taken together, our results provide compelling 
evidence that HSET OE drives tumor progression through 
multiple mechanisms that include (i) enhancement of 
tumor cell proliferation rates, (ii) increasing aneuploidy 
through centrosome clustering, upregulation of Aurora-B 
and compromised SAC function and (iii) promoting 
pro-survival signaling. Clearly, these findings that argue 
for the existence of a causative link between nuclear 
HSET accruement and tumor aggressiveness, have far-
reaching clinical implications, including unlocking 
the potential of HSET nuclear expression serving as a 
prognostic biomarker, and HSET taking shape as a cancer-
selective therapeutic target for the design and preclinical 
development of small-molecule HSET inhibitors for non-
toxic breast cancer therapy. 
MATERIALS AND METHODS
In silico analysis of HSET gene expression
One channel micro array data were collected from 
the Gene Expression Omnibus (GEO) database and 
processed using Robust Multiarray (RMA) normalization 
and were further used for gene expression analysis. The 
list of the GSE ID’s are given in Supp. Table 1. Log2-
transformed HSET expression levels are plotted in Fig. 1 
for each of the glioblastoma, lung, breast, colon cervical 
cancer and leukemia patients compared with their normal 
pairs. Statistical analysis was performed using Student’s 
t-test. The criterion for statistical significance was p< 0.05. 
Clinical tissue samples
All paraffin-embedded tissue slides were 
commercially obtained (from Accumax and US Biomax). 
A subset of well-annotated tissue microarrays (339 
biospecimens) with information on clinical outcomes 
(n=163) were obtained from Emory University Hospital. 
The Emory Institutional Review Board approval was 
obtained for all aspects of the study. 
Immunohistochemistry, scoring and statistics
For immunohistochemical staining, the TMAs 
were first deparaffinized and then rehydrated in a series 
of ethanol baths (100%, 90%, 75% and 50%). Antigen 
retrieval was achieved by citrate buffer (pH 6.0) in a 
pressure-cooker (15 psi) for 30 min. Immunostaining for 
HSET (1:1000 dilution) was performed using a rabbit 
polyclonal antibody which was a generous gift from 
Claire Walczak (Indiana University). Enzymatic antibody 
detection was performed using Universal LSAB + kit/HRP 
(DAKO, CA, USA). HSET staining was scored for both 
the nuclear and cytoplasmic localization as an intensity 
and frequency score by an experienced pathologist. A 
relative intensity score was represented as 0 = none, 1 = 
low, 2 = moderate, or 3 = high and frequency score was 
represented as the percentage of cell nuclei or cytoplasms 
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demonstrating HSET positivity. 
Statistical methods
Statistical analyses were performed using SAS 
Version 9.3 with HSET WI considered as a continuous 
variable in all the required analysis tests. Kaplan-Meier 
survival curves were generated for patient outcomes (OS 
and PFS) stratified by negative and positive HSET WI 
groups. Survival differences between the groups were 
assessed using the log-rank test.
Cell culture and transfection
HeLa-HSET-GFP cells were generously provided 
by Claire Walczak (Indiana University). HeLa, HeLa-
HSET-GFP and MDA-MB-231 cells were grown in 
DMEM supplemented with 10% FBS and 1% penicillin/
streptomycin. Briefly, cells were seeded onto 100-mm 
plates 1 day prior to transfection. Plasmid DNA (5 μg) 
and 15 μl of DharmaFECT 4 transfection reagent (Thermo 
Scientific, PA, USA) were used for each transfection. 
HSET-pEGFP plasmid was generously provided by Dr. 
Walczak. Cells overexpressing HSET were selected in 
the medium containing G418 (400 μg/ml). The G418-
resistant colonies were collected and examined for HSET 
expression. SMARTpool: ON-TARGETplus KIFC1 
siRNA (Dharmacon, PA, USA) was used to knockdown 
HSET in MDA-MB-231 cells.
Cellular protein preparation, western blotting, 
immunofluorescence and antibodies
Cells were cultured to ~70% confluence and protein 
lysates were collected following transfection or otherwise. 
Fresh frozen tissue sections were first sonicated and 
lysates were then prepared. The immune-reactive bands 
corresponding to the respective primary antibodies 
were visualized by the Pierce ECL chemiluminescence 
detection kit (Thermo Scientific). β-actin was used 
as loading control. For immunofluorescence staining, 
cells grown on glass coverslips were fixed with −20 °C 
methanol for 10 min and blocked by incubating with 2% 
bovine serum albumin/PBS/0.05% Triton X-100 at 37 °C 
for 1h. Specific primary antibodies were incubated with 
coverslips for 1h at 37 °C at the recommended dilution. 
The cells were washed with 2% bovine serum albumin/
PBS for 10 min at room temperature before incubating 
with a 1:2000 dilution of Alexa 488- or 555-conjugated 
secondary antibodies. Cells were mounted with Prolong 
Gold antifade reagent that contains 4′,6-diamidino-2-
phenylindole (Invitrogen). Polyclonal rabbit anti-HSET 
antibody was provided by Dr. Claire Walczak. Antibodies 
against α-tubulin and β-actin were from Sigma (St. Louis, 
MO, USA). Antibodies against γ-tubulin, α-tubulin and 
β-actin were from Sigma (St. Louis, MO, USA). Anti-
Mad2 antibody was from BD Biosciences (Pharmingen, 
San Jose, CA, USA). Antibodies against p-Bcl2 and 
cleaved caspase-3 were from Cell Signaling (Danvers, 
MA, USA). Alexa 488- or 555- conjugated secondary 
antibodies were from Invitrogen (Carlsbad, CA, USA). 
Anti-Mad1 antibody was a generous gift from Andrea 
Musacchio affiliation. Anti-Ki67 antibody was from 
Abcam (Cambridge, MA, USA). Horseradish peroxidase-
conjugated secondary antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). 
Kinase activity assay
To examine cdk1 and Aurora-B kinase activity, 
respective primary antibodies were used to selectively 
immunoprecipitate protein-containing complexes from 
cell lysates. The resulting immunoprecipitate was 
incubated with pure histone-H3 protein in the presence 
of 32P-labelled ATP and kinase buffer. The kinase 
assay reaction allowed immunoprecipitated cdk1 to 
phosphorylate histone-H3 in vitro, the extent of which was 
measured by immunoblotting using phosphohistone-H3 
antibody from Cell Signaling (MA, USA). Histone-H3 
protein was from Millipore (MA, USA) and ATP was from 
Cell Signaling.
Fluorescence in situ hybridization
The samples from tumor cell lines or tumor tissue 
were hybridized by 2-color FISH with an HSET-specific 
BAC probe (RPCI-11 602P21, green) and a chromosome 
6 centromere probe (CH514-7B4, red) (BACPAC). The 
HSET and centromere 6 probes were labeled with Cy3-
dUTP (red) and FITC-dUTP (green), respectively, and 
hybridized with nuclei from cell lines or tumor tissue 
samples. Plasmids for production of a particular FISH 
probe were combined in equimolar amounts (55–70 pM). 
Nick translation was performed on 2 µg of this substrate 
by using Nick translation kit (Abbott Molecular, IL, 
USA). The translation product was denatured for 3 mins 
at 95°C followed by fast cooling on ice and confirmed in 
1.5% agarose gel electrophoresis as a smear of fragments 
ranging between 100 and 300 bp. A 2 min denaturation 
at 76°C was followed by overnight (12–16h) incubation 
at 37°C. Hybridization of the FISH probes was carried 
out in LSI/WCP hybridization buffer (Abbott Molecular, 
IL, USA). The slides were counterstained with DAPI 
(Invitrogen, NY, USA) and Zeiss LSM 700 confocal 
microscope was used to capture FISH images. Results 
were expressed as a ratio of the number of copies of the 
HSET gene to the number of chromosome 6–centromeric 
markers. 
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Flow cytometry
Trypsinized cells were resuspended in PBS at 106 
cells/ml. Cells were then fixed by addition of ice-cold 
70% ethanol. Ethanol-fixed cells were kept overnight at 
4°C before staining. Cells were pelleted and washed twice 
with PBS. Cell pellets were incubated for an hour at room 
temperature with mouse anti-MPM-2 antibody (Millipore, 
MA, USA), followed by1h incubation with Alexa-488 
anti-mouse secondary antibody (Life Technologies, 
NY, USA). Finally cells were washed, pelleted and 
resuspended in PI containing isotonic buffer (0.1 mg/
ml) and 0.5% Triton X-100. Cell cycle distribution was 
determined by flow cytometry using an LSRFortessa Flow 
cytometer (BD Biosciences, CA, USA) and analyzed 
using Flowjo software (Tree Star, OR, USA).
Trypan Blue cell exclusion assay
Cells were cultured to ~70% confluence followed 
by centrifuging and pellet was resuspended in 1 ml culture 
medium. 0.1 mL of 0.4% trypan blue solution was then 
added to 1 mL of cell suspension. A hemacytometer 
was loaded with 10 µl of the solution and examined 
immediately under a microscope. Live (white) and dead 
(blue) cells were counted and percent cell viability was 
calculated using the following formula: percent viable 
cells = [1.00 – (Number of live cells ÷ Number of total 
cells)] × 100.
BrdU incorporation assay
Asynchronous proliferating HeLa and HeLa-HSET-
GFP cells were grown on coverslips to a confluency of 
~70% and then incorporated with 10µM BrdU for 1h 
followed by fixation with 70% ethanol at room temperature 
and immersion in 0.07 N NaOH for 2 minutes (which 
was then neutralized with PBS, pH 8.5). Coverslips were 
then incubated in 2% bovine serum albumin/PBS.0.05% 
Triton X-100 at 37 °C for 1h followed by immunostaining 
using a 1:1000 dilution of Anti-BrdU-FITC antibody (BD 
Biosciences, San Jose, CA, USA). BrdU positive cells, 
indicative of cell proliferation, were captured on a Zeiss 
Axioplan-2 fluorescence microscope (20X objective).
Immunoprecipitation and endogenous 
ubiquitination analysis
 MDA-MB-231 cells were transiently transfected 
with control vector, HSET-pEGFP plasmid or SMARTpool 
siRNA as described above and lysates were collected. Cell 
lysates were clarified by centrifugation at 10,000 rpm, 
and the supernatants (500 μg of protein) were subjected 
to immunoprecipitation with 4 µl of anti-HSET or anti-
survivin antibodies. After overnight incubation at 4°C, 
protein A-agarose beads were added and left at 4°C 
overnight. Immunocomplexes were then subjected to 
Western blot analysis as described previously. Western 
blot analysis with anti-ubiquitin antibody (Life Sensors, 
PA, 1:500) was performed by first incubating the PVDF 
membrane with 0.5% glutaraldehyde/PBS pH 7.0 for 20 
min and then probing for the antibody.
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